US OptionsDetailed Quotes
TMDX240920P80000
- 0.05
- -0.15-75.00%
15min DelayClose Sep 17 15:59 ET
0.05High0.05Low
0.05Open0.20Pre Close1 Volume14 Open Interest80.00Strike Price5.00Turnover308.89%IV48.78%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0037Delta0.0003Gamma3121.60Leverage Ratio-0.0463Theta0.0000Rho-11.47Eff Leverage0.0015Vega
TransMedics Stock Discussion
Sign in to post a comment
The most important number of the day wa CPI number. Inflation in August declined to its lowest level since February 2021, according to a Labor Department report Wednesday that also showed a key measure higher than expected, setting the stage for an expected quarter percentage point rate cut from the Federal Reserve.
Indeed, while the headline CPI increased 0.2% for the month, in line with the Dow Jones consensus, the core CPI, which excludes volatile food and energy prices, inc...
Indeed, while the headline CPI increased 0.2% for the month, in line with the Dow Jones consensus, the core CPI, which excludes volatile food and energy prices, inc...
17
7
Owning stocks isn't enough -- you must understand what these companies do. If you can't summarize their business in one sentence, you might not truly know them.
Here are the one-liners for each stock in my portfolio 🧐
1. $CrowdStrike (CRWD.US)$ | Crowdstrike
• Their Falcon platform uses artificial AI and cloud technology to detect and respond to cyber threats by offering endpoint security, threat intelligence, and cyberattack response services.
2. $Snowflake (SNOW.US)$ | Snowflake
• A cloud-...
Here are the one-liners for each stock in my portfolio 🧐
1. $CrowdStrike (CRWD.US)$ | Crowdstrike
• Their Falcon platform uses artificial AI and cloud technology to detect and respond to cyber threats by offering endpoint security, threat intelligence, and cyberattack response services.
2. $Snowflake (SNOW.US)$ | Snowflake
• A cloud-...
87
4
TransMedics Group's trend of growing ROCE and increasing capital employed suggests profitable reinvestment opportunities, potentially leading to a multi-bagger performance. The stock's solid return to shareholders over the last three years indicates investor recognition of these changes.
1
$Advanced Micro Devices (AMD.US)$ was obvious to buy at $100 and many waited
$Celsius Holdings (CELH.US)$ at $48 (this year) was the easiest money and people waited.
$Palantir (PLTR.US)$ at $14 was extremely undervalued and many waited
$Meta Platforms (META.US)$ was obvious to buy at $200 and everyone waited
$CrowdStrike (CRWD.US)$ was a clear buy at $150 and people waited
$TransMedics (TMDX.US)$ at $38 with a market cap of $1 Billion was a steal and nobody wanted to buy it.
Focus on the essentials: align...
$Celsius Holdings (CELH.US)$ at $48 (this year) was the easiest money and people waited.
$Palantir (PLTR.US)$ at $14 was extremely undervalued and many waited
$Meta Platforms (META.US)$ was obvious to buy at $200 and everyone waited
$CrowdStrike (CRWD.US)$ was a clear buy at $150 and people waited
$TransMedics (TMDX.US)$ at $38 with a market cap of $1 Billion was a steal and nobody wanted to buy it.
Focus on the essentials: align...
9
3
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
7
Insider selling over the past year, particularly in recent months, may indicate insiders believe shares are overpriced. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership shows alignment with shareholders, but past sales warrant caution.
TransMedics Group's significant top-line growth is undermined by its negative EBIT, liabilities outstripping cash and near-term receivables by $75m, and increased cash burn over the past year, constituting substantial risk.
Oppenheimer analysts hail TransMedics' recent quarter as 'blockbuster', emphasizing its long-term strategy to overcome short term challenges. The game-changing potential of the Organ Care System technology to reshape organ preservation and transport is also highlighted.
1
wheres everyone
and why did this run up all on its own
and why did this run up all on its own
No comment yet
EZ_money :
Dee-Mat : And you don’t think they fluffed the actual rate? They lie and then change the numbers months later
Wardogone11 Dee-Mat : Then why not lie and say it’s down 7%?
EZ_money Wardogone11 : lies have to be somewhat believable don't they? otherwise who's going to believe that story
103527567 Wardogone11 : because a lie has to be somewhat believable
View more comments...